Critical review of the determination process by the Japanese reviewing authority in approving the additional efficacy of fludarabine phosphate.
Narimatsu
Hiroto
H
Oiso
Giichiro
G
Ono
Shunsuke
S
Kami
Masahiro
M
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017277:Drug Approval; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007564:Japan; D056687:Off-Label Use; D019172:Transplantation Conditioning; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate